Evaluating the Role of Pre-existing Resolvins in the Resolution of ICU Delirium
Key facts
- Who runs it
- Université Libre de Bruxelles
- Where
- Belgium1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Started
- 7 Oct 2023
- Ended
- 30 Jun 2024
- Type of study
- Observational
- Treatments tested
- Study group
- Record updated
- 30 March 2025
- Why it stopped
- COVID-19
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (10)Hide the full registry criteria
Who can take part
- Non-ventilated, non-sedated adult patients with a planned ICU stay >72 hours. - - patients admitted due to an exacerbation of COPD
- patients admitted due to severe trauma
- patients admitted due to cardiogenic shock
- patients admitted due to septic shock
Who cannot take part
- Patients with known recreational drug and alcohol (ab)use
- Patients with known neuro-psychiatric disorders
- Patients who don't understand English, French or Dutch
- Patients who are visually/auditory impaired (without glasses/ hearing aid)
- Patients with a neurological trauma
- Patients on ECMO
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
As patient management is improving, more and more ICU survivors are being confronted with cognitive dysfunction and this well after their hospital stay.
Read full original descriptionShow less
In the ICU, delirium rates have been reported to be as high at 81%. Delirium is associated with patient and family stress, increased hospital costs, increased duration of stay, escalation of care and increased mortality and morbidity.
The physiopathology of ICU cognitive impairment is complex and involves an inflammatory cascade Recently, the role of 'resolvins' derived from omega-3 fatty acids has been studied in the resolution of inflammation.
Therefore, this hypothesis of this study is that ICU patients with higher serum levels of resolvins at ICU admission, ICU day 2 and day 5 will have a lesser degree of cognitive impairment on day 5 of ICU stay.
Treatments tested
- Study group
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 30 March 2025